Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

36.10
-0.7700-2.09%
Post-market: 36.100.00000.00%16:34 EDT
Volume:1.54M
Turnover:56.04M
Market Cap:5.86B
PE:-16.71
High:37.01
Open:36.10
Low:35.78
Close:36.87
52wk High:43.73
52wk Low:3.72
Shares:162.31M
Float Shares:143.00M
Volume Ratio:0.57
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-73.70%
ROA:-32.93%
PB:10.71
PE(LYR):-14.15

Loading ...

LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)

TIPRANKS
·
Feb 21

H.C. Wainwright Sticks to Their Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Feb 20

Jefferies Sticks to Its Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
Feb 18

Stock Track | Cogent Biosciences Soars 5.42% Intraday on Positive Analyst Ratings

Stock Track
·
Feb 18

Wedbush Remains a Buy on Cogent Biosciences (COGT)

TIPRANKS
·
Feb 18

Analysts Conflicted on These Healthcare Names: Danaher (DHR), Cogent Biosciences (COGT) and Masimo (MASI)

TIPRANKS
·
Feb 18

Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains

TIPRANKS
·
Feb 18

Cogent Biosciences Q4 net loss widens

Reuters
·
Feb 17

Cogent Biosciences posts FY2025 cash and cash equivalents of USD 900.8 million

Reuters
·
Feb 17

BRIEF-Cogent Biosciences Q4 Operating Expenses USD 99.493 Million

Reuters
·
Feb 17

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Feb 17

Cogent Biosciences Q4 Net Income USD -102.492 Million

THOMSON REUTERS
·
Feb 17

Cogent Biosciences Unveils Positive SUMMIT Trial Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis

Reuters
·
Feb 10

Cogent Biosciences Submits New Drug Application for Bezuclastinib in Nonadvanced Systemic Mastocytosis

Reuters
·
Feb 10

Cogent Biosciences reicht Zulassungsantrag für Bezuclastinib bei der FDA ein

Reuters
·
Feb 10

U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday

Reuters
·
Feb 10

Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News

Simply Wall St.
·
Feb 05

13D Filings -- Barrons.com

Dow Jones
·
Jan 31

Raymond James Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Jan 27

FDA Grants Breakthrough Therapy Designation to Cogent Biosciences' Bezuclastinib Combination for GIST

Reuters
·
Jan 26